THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [4.20] ID: TIP-MED-000064

Voglibose

Active Ingredient / Scientific Identity: Voglibose • Class: Intestinal Alpha-Glucosidase Inhibitor (Schedule H)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Voglibose ([4.20] | ID: TIP-MED-000064) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/4-20-voglibose/
Generic / Entity NameVoglibose ([4.20])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassIntestinal Alpha-Glucosidase Inhibitor (Schedule H)
Available Dosage FormsTablets / Mouth-Dissolving Tablets: 0.2 mg, 0.3 mg; FDCs with Metformin + Glimepiride (Volix Trio, Glycomet Tr
Regulatory ClassificationSchedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this pre
Key Warning & Review DateRenal: <2% systemic absorption, but avoid in severe renal failure (eGFR <30 mL/min) per SmPC. Hepatic: Avoid in decompensated
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H & Schedule G Prescription Drug ('Caution:✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Voglibose (TIP-MED-000064, Reference Code [4.20]) is classified under Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Intestinal Alpha-Glucosidase Inhibitor (Schedule H). Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.20], p. 54): Volix (Sun), Vobose (Sun), Prandial MD (Cipla), PPG (Abbott) — Strengths & Dosage Forms: Tablets / Mouth-Dissolving Tablets: 0.2 mg, 0.3 mg; FDCs with Metformin + Glimepiride (Volix Trio, Glycomet Trio)
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.20], p. 54): Volix (Sun), Vobose (Sun), Prandial MD (Cipla), PPG (Abbott) — Strengths & Dosage Forms: Tablets / Mouth-Dissolving Tablets: 0.2 mg, 0.3 mg; FDCs with Metformin + Glimepiride (Volix Trio, Glycomet Trio)
Dosage Forms & Available Strengths:
Tablets / Mouth-Dissolving Tablets: 0.2 mg, 0.3 mg; FDCs with Metformin + Glimepiride (Volix Trio, Glycomet Trio)
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Intestinal Alpha-Glucosidase Inhibitor (Schedule H) acting on target receptor/enzyme pathways in Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04): clinical efficacy is mediated via Intestinal Alpha-Glucosidase Inhibitor (Schedule H) for Control of postprandial hyperglycaemia in Type 2 Diabetes Mellitus (especially in high-carbohydrate Indian rice/roti diets).

4. Therapeutic Indications & Evidence-Supported Uses

  • Control of postprandial hyperglycaemia in Type 2 Diabetes Mellitus (especially in high-carbohydrate Indian rice/roti diets)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: 0.2 mg or 0.3 mg PO THREE times daily taken with the very first bite of Breakfast, Lunch, and Dinner

Administration & Meal Timing: MUST be chewed/swallowed WITH THE FIRST BITE of each main carbohydrate meal (ineffective if taken 30 min before or after eating!) | With First Bite of Breakfast, Lunch & Dinner

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: <2% systemic absorption, but avoid in severe renal failure (eGFR <30 mL/min) per SmPC. Hepatic: Avoid in decompensated cirrhosis
Elimination & Renal Adjustment:
Renal: <2% systemic absorption, but avoid in severe renal failure (eGFR <30 mL/min) per SmPC. Hepatic: Avoid in decompensated cirrhosis
Hepatic Impairment Considerations:
Renal: <2% systemic absorption, but avoid in severe renal failure (eGFR <30 mL/min) per SmPC. Hepatic: Avoid in decompensated cirrhosis

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in inflammatory bowel disease (ulcerative colitis, Crohn's), intestinal obstruction/hernia, severe ketosis, and severe renal/hepatic failure

Key Clinical Precautions: Renal: <2% systemic absorption, but avoid in severe renal failure (eGFR <30 mL/min) per SmPC. Hepatic: Avoid in decompensated cirrhosis

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Flatulence, abdominal distension, meteorism, soft stools/diarrhoea (due to colonic bacterial fermentation of undigested disaccharides — fewer GI side effects than Acarbose)
  • Pneumatosis cystoides intestinalis (rare), paralytic ileus, hepatotoxicity; CRITICAL HYPOGLYCAEMIA RULE: If hypoglycaemia occurs in a patient taking Voglibose + Sulfonylurea/Insulin, ORDINARY TABLE SUGAR (SUCROSE) WILL NOT WORK because Voglibose blocks sucrase! Must treat with pure GLUCOSE (Glucon-D / Dextrose)!
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Charcoal and digestive enzyme preparations (amylase/pancreatin) reduce Voglibose efficacy; decreases Digoxin bioavailability slightly

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: TWO ESSENTIAL COUNTER POINTS: (1) Take right with the first bite of food; (2) If you also take Glimepiride or Insulin and get low blood sugar, ordinary cane sugar (cheeni) will NOT raise your sugar fast — always carry pure Glucose powder (Glucon-D)!
  • Meal & Clock Timing Instruction: MUST be chewed/swallowed WITH THE FIRST BITE of each main carbohydrate meal (ineffective if taken 30 min before or after eating!) (With First Bite of Breakfast, Lunch & Dinner)
  • Missed Dose Protocol: If remembered after the meal is finished, SKIP the dose completely (do not take on an empty stomach)
  • Geriatric Dispensing Pearl: Safe in older adults without intrinsic hypoglycaemia, but monitor for GI bloating/diarrhoea

Storage, Stability & Dispensing Safeguards: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 04 [4.20] (p. 54)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/4-20-voglibose/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.